Plasmacytoid urothelial carcinoma: Difference between revisions

Jump to navigation Jump to search
Michael (talk | contribs)
Michael (talk | contribs)
 
(6 intermediate revisions by the same user not shown)
Line 11: Line 11:
| IHC        = AE1/AE3 +ve, EMA +ve, CK7 +ve, CK20 +ve, CD138 +ve, p63 +ve/-ve
| IHC        = AE1/AE3 +ve, EMA +ve, CK7 +ve, CK20 +ve, CD138 +ve, p63 +ve/-ve
| EM        =
| EM        =
| Molecular  =
| Molecular  = CDH1 loss of function mutations
| IF        =
| IF        =
| Gross      =
| Gross      =
Line 73: Line 73:
*[[CD138]] (15 +ve/16 cases).
*[[CD138]] (15 +ve/16 cases).
*p63 (11 +ve/16 cases).
*p63 (11 +ve/16 cases).
Others:
*E-cadherin -ve (0 positive of 4 cases<ref name=pmid20818341>{{Cite journal  | last1 = Lim | first1 = MG. | last2 = Adsay | first2 = NV. | last3 = Grignon | first3 = DJ. | last4 = Osunkoya | first4 = AO. | title = E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma. | journal = Mod Pathol | volume = 24 | issue = 2 | pages = 241-7 | month = Feb | year = 2011 | doi = 10.1038/modpathol.2010.187 | PMID = 20818341 }}</ref>).
*HER2 +ve/-ve.
**In a series of 6 cases: 4 cases were 3+, one case was 2+, one case negative.<ref name=pmid27034533>{{Cite journal  | last1 = Kim | first1 = B. | last2 = Kim | first2 = G. | last3 = Song | first3 = B. | last4 = Lee | first4 = C. | last5 = Park | first5 = JH. | last6 = Moon | first6 = KC. | title = HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder. | journal = Dis Markers | volume = 2016 | issue =  | pages = 8463731 | month =  | year = 2016 | doi = 10.1155/2016/8463731 | PMID = 27034533 }}</ref>
**HER2 status ''not'' a predictor of survival in UCC patients.<ref name=pmid25720673>{{Cite journal  | last1 = Bellmunt | first1 = J. | last2 = Werner | first2 = L. | last3 = Bamias | first3 = A. | last4 = Fay | first4 = AP. | last5 = Park | first5 = RS. | last6 = Riester | first6 = M. | last7 = Selvarajah | first7 = S. | last8 = Barletta | first8 = JA. | last9 = Berman | first9 = DM. | title = HER2 as a target in invasive urothelial carcinoma. | journal = Cancer Med | volume = 4 | issue = 6 | pages = 844-52 | month = Jun | year = 2015 | doi = 10.1002/cam4.432 | PMID = 25720673 }}</ref>


==Molecular==
==Molecular==
*CDH1 loss of function - common.<ref name=pmid26901067>{{Cite journal  | last1 = Al-Ahmadie | first1 = HA. | last2 = Iyer | first2 = G. | last3 = Lee | first3 = BH. | last4 = Scott | first4 = SN. | last5 = Mehra | first5 = R. | last6 = Bagrodia | first6 = A. | last7 = Jordan | first7 = EJ. | last8 = Gao | first8 = SP. | last9 = Ramirez | first9 = R. | title = Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. | journal = Nat Genet | volume =  | issue =  | pages =  | month = Feb | year = 2016 | doi = 10.1038/ng.3503 | PMID = 26901067 }}</ref>
*CDH1 loss of function - common.<ref name=pmid26901067>{{Cite journal  | last1 = Al-Ahmadie | first1 = HA. | last2 = Iyer | first2 = G. | last3 = Lee | first3 = BH. | last4 = Scott | first4 = SN. | last5 = Mehra | first5 = R. | last6 = Bagrodia | first6 = A. | last7 = Jordan | first7 = EJ. | last8 = Gao | first8 = SP. | last9 = Ramirez | first9 = R. | title = Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. | journal = Nat Genet | volume =  | issue =  | pages =  | month = Feb | year = 2016 | doi = 10.1038/ng.3503 | PMID = 26901067 }}</ref>
==Sign out==
<pre>
Urinary Bladder Tumour, Transurtheral Resection:
- INVASIVE HIGH-GRADE UROTHELIAL CARCINOMA with plasmacytoid morphology.
-- Invasion into the muscularis propria.
-- Please see tumour summary.
</pre>


==See also==
==See also==